Last reviewed · How we verify
Dexmedetomidine, ketamine and lidocaine
Dexmedetomidine, ketamine and lidocaine is a Small molecule drug developed by Tanta University. It is currently FDA-approved.
Dexmedetomidine, ketamine, and lidocaine, marketed by Tanta University, are established anesthetic agents with a key composition patent expiring in 2028. The combination's primary strength lies in its well-documented efficacy and safety profile, supported by key trial results. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Dexmedetomidine, ketamine and lidocaine |
|---|---|
| Sponsor | Tanta University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Cardiac Index and General Anesthesia Without Opioid. (PHASE2, PHASE3)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
- Transition From Acute to Chronic Opioid Use and Chronic Pain (EARLY_PHASE1)
- General Anesthesia Versus Sedation By Dexmedetomidine and Ketamine With Local Infiltration for Percutaneous Transcatheter Closure of Atrial Septal Defect in Pediatric Patients (NA)
- Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery (NA)
- COMPARISON OF OPIOID-FREE AND OPIOID-BASED ANESTHESIA TECHNIQUES ON qNOX INDEX IN ABDOMINAL SURGERY UNDER GENERAL ANESTHESIA (NA)
- Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine, ketamine and lidocaine CI brief — competitive landscape report
- Dexmedetomidine, ketamine and lidocaine updates RSS · CI watch RSS
- Tanta University portfolio CI